Non-vitamin K antagonist oral anticoagulants and sport

被引:2
|
作者
Romano, Silvio [1 ]
Salustri, Elisa [1 ]
Robles, Antonio G. [2 ]
Calo, Leonardo [2 ]
Penco, Maria [1 ]
Sciarra, Luigi [2 ]
机构
[1] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy
[2] Casilino Polyclin Hosp, Dept Cardiol, Rome, Italy
来源
MINERVA CARDIOANGIOLOGICA | 2020年 / 68卷 / 02期
关键词
Pharmacologic actions; Athletes; Anticoagulants; Atrial fibrillation; FACTOR XA INHIBITOR; POTENTIALLY ARRHYTHMOGENIC CONDITIONS; ATRIAL-FIBRILLATION PATIENTS; TIME PHYSICAL-ACTIVITY; CARDIAC REHABILITATION; COMPETITIVE SPORTS; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; RISK-FACTORS; DABIGATRAN;
D O I
10.23736/S0026-4725.20.05177-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Physical activity is worldwide recommended for its benefits on cardiovascular system. There is an increasing number of people of all ages that approach sport activity both as leisure time physical activity and as competitive sport. It is always more frequent the request even from older subjects and cardiac patients to be allowed to practice physical activity. Some problems could arise when these subjects present or develop pathologic conditions that require specific pharmacological treatment, in particular an anticoagulation therapy. This review focalizes on the manaaement of oral anticoagulant therapy (OAT) in patients practicing sport activity, especially due to atrial fibrillation and deep vein thrombosis, which represent two highly prevalent conditions, particularly with increasing age. Official recommendations in this field may appear limiting for patients, forbidding in the majority of cases sports at risk of trauma and consequent bleeding. These recommendations still resent the heritage of the "traditional" management of OAT, mainly represented by vitamin-K antagonists (VKAs). The non-vitamin K antagonist oral anticoagulants, with their more favorable pharmacokinetic-pharmacodynamic profile compare to VKAs, may now represent an opportunity to modify the approach to sport activity in patients with an indication to OAT. This review of the literature deals with possible strategies to overcome the present limitations for OAT subjects willing to pursue a healthy lifestyle, that include sport activity, minimizing at the same time their risk of bleeding.
引用
收藏
页码:98 / 109
页数:12
相关论文
共 50 条
  • [41] Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
    Fanaroff, Alexander C.
    Vora, Amit N.
    Lopes, Renato D.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A19 - A31
  • [42] NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS DO NOT INCREASE CEREBRAL MICROBLEEDS
    Saito, Tsukasa
    Kawaura, Yuichiro
    Sato, Nobuyuki
    Hasebe, Naoyuki
    [J]. JOURNAL OF HYPERTENSION, 2016, 34 : E354 - E354
  • [43] Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
    Gelosa, Paolo
    Castiglioni, Laura
    Tenconi, Marco
    Baldessin, Ludovico
    Racagni, Giorgio
    Corsini, Alberto
    Bellosta, Stefano
    [J]. PHARMACOLOGICAL RESEARCH, 2018, 135 : 60 - 79
  • [44] Non-Vitamin K Antagonist Oral Anticoagulants Do Not Increase Cerebral Microbleeds
    Saito, Tsukasa
    Kawamura, Yuichiro
    Sato, Nobuyuki
    Kano, Kohei
    Takahashi, Kae
    Asanome, Asuka
    Sawada, Jun
    Katayama, Takayuki
    Hasebe, Naoyuki
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (06): : 1373 - 1377
  • [45] Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
    Yang, Hayang
    Veldtman, Gruschen R.
    Bouma, Berto J.
    Budts, Werner
    Niwa, Koichiro
    Meijboom, Folkert
    Scognamiglio, Giancarlo
    Egbe, Alexander Chima
    Schwerzmann, Markus
    Broberg, Craig
    Morissens, Marielle
    Buber, Jonathan
    Tsai, Shane
    Polyzois, Ioannis
    Post, Martijn C.
    Greutmann, Matthias
    Van Dijk, Arie
    Mulder, Barbara J. M.
    Aboulhosn, Jamil
    [J]. OPEN HEART, 2019, 6 (01):
  • [46] Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants
    van Vugt, Stijn P. G.
    Brouwer, Marc A.
    Verheugt, Freek W. A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (20) : 2577 - 2578
  • [47] Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury
    Douros, Antonios
    Azoulay, Laurent
    Yin, Hui
    Suissa, Samy
    Renoux, Christel
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (10) : 1105 - 1113
  • [48] Measuring and Reversing the Effect of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)
    Silvain, Johanne
    Hauguel, Marie
    Kerneis, Mathieu
    Collet, Jean-Philippe
    Montalescot, Gilles
    [J]. CIRCULATION JOURNAL, 2015, 79 (02) : 289 - 291
  • [49] Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
    Thomas Gremmel
    Alexander Niessner
    Hans Domanovits
    Martin Frossard
    Gürkan Sengölge
    Barbara Steinlechner
    Thomas Sycha
    Michael Wolzt
    Ingrid Pabinger
    [J]. Wiener klinische Wochenschrift, 2018, 130 : 722 - 734
  • [50] Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
    Blann, Andrew D.
    Lip, Gregory Y. H.
    [J]. HEART, 2016, 102 (12) : 975 - 983